Customer Demand Communication and Project Design
Our team collaborates to understand your research objectives, tailoring experimental design for a solid project foundation.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
At Creative Biolabs, we offer comprehensive deoxyribozyme-based anti-monkeypox drug discovery solutions. Leveraging our deep scientific expertise and cutting-edge platforms, we empower clients to accelerate the identification and development of highly effective antiviral therapeutics against Monkeypox virus (MPXV), addressing a critical global health need.
Monkeypox virus (MPXV), a member of the Orthopoxvirus genus within the Poxviridae family, is a zoonotic pathogen. Characterized by its large, brick-shaped structure and a double-stranded DNA genome, MPXV carries all the essential genetic information for its replication, transcription, assembly, and egress. The disease it causes, Monkeypox, typically presents with fever, headache, muscle aches, and a distinctive rash that progresses through several stages, posing a particular threat to vulnerable populations and necessitating urgent therapeutic interventions.
Deoxyribozymes, or DNAzymes, are single-stranded DNA molecules possessing catalytic activity, primarily the ability to cleave RNA. Unlike protein enzymes, their DNA nature provides enhanced stability, making them robust candidates for therapeutic applications. Specifically, deoxyribozymes can be engineered to recognize and precisely cut target messenger RNA (mRNA) sequences within a pathogen, thereby inhibiting the production of essential viral proteins and disrupting the pathogen's life cycle. This precision and catalytic turnover make them powerful tools in the fight against viral infections.
Fig.1 Mechanism of action of DNAzyme.1
Creative Biolabs provides an end-to-end service for the discovery and development of deoxyribozyme-based anti-Monkeypox drugs. Our integrated platform combines advanced bioinformatics, molecular design, high-throughput screening, and rigorous validation to deliver optimized therapeutic candidates. We are dedicated to supporting your journey from initial target identification through to preclinical evaluation, ensuring a robust and efficient drug discovery pipeline.
We utilize advanced genomic analysis and bioinformatics to pinpoint highly conserved and functionally critical RNA sequences within the MPXV genome, ensuring optimal targets for deoxyribozyme design. This includes transcripts essential for viral replication, assembly, or immune evasion.
Our proprietary algorithms guide the design of custom deoxyribozyme libraries, focusing on superior binding affinity, enhanced catalytic efficiency, and improved stability through strategic chemical modifications (e.g., phosphorothioate linkages).
Our automated HTS platforms enable the rapid evaluation of thousands of deoxyribozyme candidates against specific MPXV RNA targets in vitro, efficiently identifying lead molecules with potent cleavage activity.
Promising candidates undergo rigorous testing in cell culture models infected with MPXV. We assess their ability to inhibit viral replication, reduce viral load, and mitigate virus-induced cytopathic effects, employing advanced imaging and quantitative PCR techniques.
We evaluate the absorption, distribution, metabolism, and excretion (ADME) properties of lead deoxyribozymes in relevant animal models. This includes assessing systemic exposure, tissue distribution, and half-life to inform dosing strategies.
Our services include measuring the biological effect of the deoxyribozyme in animal models, such as target RNA cleavage in infected tissues or reduction in viral load, correlating drug exposure with therapeutic response.
We design and execute preclinical efficacy studies in established animal models of Monkeypox infection. These studies assess the deoxyribozyme's ability to reduce disease severity, viral shedding, and improve survival outcomes, providing critical data for further development.
Our team collaborates to understand your research objectives, tailoring experimental design for a solid project foundation.
Once the design is finalized, a service agreement outlines deliverables, timelines, and IP. Managers and leads are assigned, initiating project launch and resource allocation.
Meticulous execution of agreed procedures, including deoxyribozyme synthesis and in vitro/ in vivo assays, ensures reliable, reproducible data through rigorous quality control.
Raw data undergoes thorough analysis with advanced tools. Comprehensive reports, including methodologies, key findings, and actionable recommendations, ensure clarity and direct research applicability.
Final results and reports are delivered securely and promptly. Creative Biolabs provides ongoing post-delivery consultation and support for seamless transition and continued research progress.
Click the button to contact us for service details and a custom quote.
Deoxyribozymes act as highly specific "molecular scissors" within infected cells to combat Monkeypox virus. Their mechanism involves two critical steps: first, the deoxyribozyme's recognition arms precisely bind to a complementary, essential sequence within the Monkeypox viral RNA, such as an mRNA transcript crucial for viral replication or protein synthesis. Second, once bound, the deoxyribozyme's catalytic core (often a 10-23 motif) cleaves the phosphodiester bond within the target RNA. This specific cleavage renders the viral RNA non-functional, effectively halting the production of vital viral proteins and disrupting the viral life cycle. The deoxyribozyme is then released, free to catalyze the cleavage of additional viral RNA molecules, demonstrating its potent catalytic turnover.
Precision Targeting
Our deoxyribozymes are meticulously designed to bind unique MPXV RNA sequences, significantly minimizing potential off-target effects on host cells and enhancing therapeutic specificity.
Catalytic Efficacy
Leveraging the inherent catalytic activity of deoxyribozymes, a single molecule can inactivate multiple viral RNA targets, leading to higher potency and potentially lower effective doses.
Enhanced Stability
We incorporate strategic chemical modifications into our deoxyribozyme designs, improving their in vivo stability and resistance to nuclease degradation, which is crucial for effective systemic delivery and sustained action.
Accelerated Discovery
Our integrated platform, combining advanced bioinformatics with high-throughput screening, significantly streamlines the drug discovery process, reducing the time and cost associated with identifying promising antiviral candidates.
Deoxyribozymes offer exceptional specificity by directly targeting and cleaving essential viral RNA sequences, which can lead to fewer off-target effects compared to many small molecule drugs. Their catalytic nature also means a single deoxyribozyme molecule can inactivate multiple viral RNA targets, potentially increasing potency and reducing the required dosage.
Our design process involves extensive bioinformatics analysis to identify highly conserved and unique RNA sequences within the Monkeypox viral genome that have minimal homology to human RNA. This meticulous selection, combined with rigorous in vitro and cellular specificity assays, ensures that our deoxyribozymes preferentially target viral components, mitigating potential host cell interactions.
Delivering nucleic acid therapeutics into cells effectively is a common challenge. We address this by incorporating chemical modifications into the deoxyribozyme structure to improve cellular uptake and stability. We also explore various delivery strategies, including lipid nanoparticles or viral vectors, depending on the specific application and target cell type, to optimize intracellular delivery.
Creative Biolabs operates with clear and transparent intellectual property agreements. Generally, any intellectual property generated directly from the services provided to a client, based on their specific project, will belong to the client. We are committed to protecting your innovations and ensuring your ownership of the discoveries made through our collaboration.
While we primarily focus on the discovery and preclinical development phases, we can certainly provide guidance and connect clients with trusted partners for large-scale synthesis and manufacturing of deoxyribozyme candidates. Our expertise extends to advising on purity requirements and formulation strategies necessary for subsequent clinical development.
After identifying a promising lead candidate, the next steps typically involve further preclinical optimization, including more extensive toxicology studies, detailed pharmacokinetic and pharmacodynamic characterization, and formulation development. Creative Biolabs can continue to support these stages through our advanced analytical services and expert consultation, guiding your candidate towards clinical trials.
If you are interested in the deoxyribozyme-based inhibition of monkeypox virus replication, or monkeypox research products, please feel free to contact us for more information.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.